Literature DB >> 9470129

Morphological substrates of dementia in parkinsonism. A critical update.

K A Jellinger1.   

Abstract

Dementia in parkinsonism is caused by a variety of central nervous system (CNS) lesions, of which the molecular and pathogenic causes are poorly understood but probably include: 1. Degeneration of subcortical ascending systems with neuronal losses in dopaminergic, noradrenergic, serotonergic, cholinergic or multiple systems including the amygdyloid nucleus; 2. limbic and/or cortical Alzheimer and/or Lewy body pathologies, with loss of synapses and neurons, and 3. a combination of these lesions or additional CNS pathologies. In general, degeneration of subcortical neuronal networks appears insufficient to induce severe mental decline although, occasionally, cognitive impairment occurs without apparent cortical lesions. On the other hand, neuritic cortical Alzheimer change showing similar or differential distribution compared to Alzheimer's disease (AD) displays a significant linear correlation with dementia in Parkinsonism. Plaques can be associated with cortical Lewy bodies and, the contribution of each to dementing processes remains unresolved. In a consecutive autopsy series of 610 patients with parkinsonism, the total prevalence of retrospectively assessed dementia was 34.6%. In Parkinson's disease (PD) of the Lewy body type, it was 30.2%, mostly associated with other brain lesions, mainly AD, while only 3.5% of "pure" PD without additional brain pathologies were demented. There was no significant difference in age and duration of illness between demented and non-demented PD patients. Secondary parkinsonian syndromes showed a higher incidence of dementia (56.3%), again with predominant Alzheimer pathology which was present in 73% of the total of demented parkinsonian patients and in almost 82% of the demented PD cases in this series. The specific contribution of cortical and subcortical lesions to mental impairment in parkinsonism, their relationship to AD, and an etiology await further elucidation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9470129     DOI: 10.1007/978-3-7091-6846-2_6

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  8 in total

1.  Smoking and dementia in male British doctors: prospective study.

Authors:  R Doll; R Peto; J Boreham; I Sutherland
Journal:  BMJ       Date:  2000-04-22

2.  The cholinergic basal forebrain in Lewy body dementia and Alzheimer's disease.

Authors:  Kurt A Jellinger
Journal:  J Neurol       Date:  2014-12-12       Impact factor: 4.849

Review 3.  Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease.

Authors:  J Kulisevsky
Journal:  Drugs Aging       Date:  2000-05       Impact factor: 3.923

4.  Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia.

Authors:  E R Bychkov; V V Gurevich; J N Joyce; J L Benovic; E V Gurevich
Journal:  Neurobiol Aging       Date:  2006-11-27       Impact factor: 4.673

5.  Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases.

Authors:  Magdalena Nutu; Philippe Bourgeois; Henrik Zetterberg; Erik Portelius; Ulf Andreasson; Stéphane Parent; Francesco Lipari; Sara Hall; Radu Constantinescu; Oskar Hansson; Kaj Blennow
Journal:  Neuromolecular Med       Date:  2012-12-07       Impact factor: 3.843

6.  Phenomenology and management of cognitive and behavioral disorders in Parkinson's disease. Rise and logic of dementia in Parkinson's disease.

Authors:  Constantin Potagas; Sokratis Papageorgiou
Journal:  Ann Gen Psychiatry       Date:  2006-08-08       Impact factor: 3.455

Review 7.  Meta-analysis of risk factors for Parkinson's disease dementia.

Authors:  Yaqian Xu; Jing Yang; Huifang Shang
Journal:  Transl Neurodegener       Date:  2016-06-01       Impact factor: 8.014

Review 8.  Adult Astrogenesis and the Etiology of Cortical Neurodegeneration.

Authors:  Tal C Mohn; Andrew O Koob
Journal:  J Exp Neurosci       Date:  2015-11-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.